Clenbuterol  (Synonyms: NAB-365)

Clenbuterol (NAB-365) is a β2-adrenergic receptor agonist with an EC₅₀ of 31.9 nM^[1]. Clenbuterol is a very potent inhibitor of the lipopolysaccharide (LPS)-induced release of TNF-α and IL-1β. Clenbuterol can inhibit the inflammatory process. Clenbuterol is a bronchodilator^[2].

Clenbuterol (NAB-365) is a selective β2-adrenergic agonist (β2/β1 ratio = 4.0). Clenbuterol is a very potent inhibitor of the lipopolysaccharide (LPS)-induced release of TNF-α and IL-1β. Clenbuterol can inhibit the inflammatory process^[2].
Clenbuterol (10-200 μM; for 24 or 48 hours) decreases the viability of C2C12 myoblasts. Clenbuterol (100 μM) significantly decreases DNA synthesis. Clenbuterol (100 μM; for 12 h) increases the proportion of cells in G0/G1 phase. Clenbuterol treatment delays cell cycle progression. Clenbuterol (100 μM) induces cell cycle arrest, but not apoptosis, in C2C12 myoblasts^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Treatment with Clenbuterol increases survival, rescues abnormalities in respiratory function and social recognition, and improves motor coordination in young male Mecp2-null (Mecp2^?/y) mice^[4].
Clenbuterol is a bronchodilator. Clenbuterol (90 μg) is administered intratracheally to five horses. Peak serum concentrations of ～230 pg/mL are detected 10 min after administration, dropping to ～50 pg/mL within 30 min and declining much more slowly thereafter. Intratracheal administration of clenbuterol shortly before race time can be detected with this serum test^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

277.19

C₁₂H₁₈Cl₂N₂O

37148-27-9

CC(C)(NCC(C1=CC(Cl)=C(C(Cl)=C1)N)O)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gilad Barnea, et al. The genetic design of signaling cascades to record receptor activation. Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):64-9.  [Content Brief]

  [2]. Olga Witkowska-Piłaszewicz, et al. The Effect of the Clenbuterol-β2-Adrenergic Receptor Agonist on the Peripheral Blood Mononuclear Cells Proliferation, Phenotype, Functions, and Reactive Oxygen Species Production in Race Horses In Vitro. Cells. 2021 Apr 17;10(4):936.  [Content Brief]

  [3]. Min Chen, et al. Clenbuterol Induces Cell Cycle Arrest in C2C12 Myoblasts by Delaying p27 Degradation through β-arrestin 2 Signaling. Int J Biol Sci. 2017 Oct 17;13(10):1341-1350.  [Content Brief]

  [4]. Nikolaos Mellios, et al. β2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome. Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9947-52.  [Content Brief]

  [5]. A F Lehner, et al. Clenbuterol in the horse: confirmation and quantitation of serum clenbuterol by LC-MS-MS after oral and intratracheal administration. J Anal Toxicol. May-Jun 2001;25(4):280-7.  [Content Brief]